Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.

ACS Chemical Neuroscience
Meghan HibickeCharles D Nichols

Abstract

Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of these two medications has not, however, been directly compared either clinically or preclinically. Further, whether or not a profound subjective existential experience is necessary for psilocybin to have antidepressant effects is unknown. To address these questions, we tested psilocybin, lysergic acid diethylamide (LSD), and ketamine in a rat model for depression. As in humans, a single administration of psilocybin or LSD produced persistent antidepressant-like effects in our model. In contrast, ketamine produced only a transient antidepressant-like effect. Our results indicate that classic psychedelics may have therapeutic efficacy that is more persistent than that of ketamine, and also suggest that a subjective existential experience may not be necessary for therapeutic effects.

References

Apr 1, 1977·Pharmacology, Biochemistry, and Behavior·M Davis, J K Walters
Dec 1, 1993·Physiology & Behavior·W P Paré, E Redei
Apr 1, 1996·Integrative Physiological and Behavioral Science : the Official Journal of the Pavlovian Society·W P Paré, S M Tejani-Butt
Jan 16, 1998·European Journal of Pharmacology·A LahmameA Armario
Jan 29, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C López-Rubalcava, I Lucki
Aug 17, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·L C SolbergE Redei
Jan 31, 2002·Psychoneuroendocrinology·Peter A RittenhouseIrwin Lucki
Jan 18, 2006·Behavioural Brain Research·Juan Carlos Brenes SáenzJaime Fornaguera Trías
Apr 5, 2007·Nature Protocols·Alicia A Walf, Cheryl A Frye
Jan 29, 2008·Current Psychiatry Reports·Diane WardenStephen R Wisniewski
Nov 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gregory V CarrIrwin Lucki
Jan 7, 2010·Basic & Clinical Pharmacology & Toxicology·Christina DallaZeta Papadopoulou-Daifoti
Feb 17, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomás PálenícekJirí Horácek
Apr 8, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Mark SinyorAnthony Levitt
Sep 8, 2010·Archives of General Psychiatry·Charles S GrobGeorge R Greer
Dec 21, 2010·Journal of Neuroscience Methods·T J MezadriC Lino-de-Oliveira
Jun 4, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Courtney S JerniganBeata Karolewicz
Jan 11, 2012·Methods in Molecular Biology·David H Overstreet
Feb 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Hanbing LuYihong Yang
May 5, 2012·Nature Protocols·David A Slattery, John F Cryan
Mar 4, 2014·Life Sciences·Helena M AbelairaJoão Quevedo
Apr 5, 2014·British Journal of Pharmacology·N Kokras, C Dalla
Oct 9, 2014·The Journal of Clinical Psychiatry·Chittaranjan Andrade
Apr 9, 2016·Journal of Basic and Clinical Pharmacy·Anroop B Nair, Shery Jacob
May 24, 2016·The Lancet. Psychiatry·Robin L Carhart-HarrisDavid J Nutt
Dec 27, 2016·Clinical Pharmacology and Therapeutics·D E NicholsC D Nichols
Mar 28, 2017·Progress in Neuro-psychopharmacology & Biological Psychiatry·Piotr GałeckiMonika Talarowska

❮ Previous
Next ❯

Citations

May 6, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marcus W MeinhardtRainer Spanagel
Nov 5, 2020·Journal of Psychopharmacology·Oskar Hougaard JefsenHeidi Kaastrup Müller
Dec 1, 2020·The International Journal of Neuropsychopharmacology·Bashkim KadriuCarlos A Zarate
Jan 27, 2021·Proceedings of the National Academy of Sciences of the United States of America·Danilo De GregorioGabriella Gobbi
Dec 18, 2020·Pharmacological Reviews·Antonio InserraGabriella Gobbi
Mar 21, 2021·Journal of Psychopharmacology·Rafael Guimarães Dos SantosSerdar Dursun
Oct 18, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gordana Nedic ErjavecNela Pivac
Apr 15, 2021·Proceedings of the National Academy of Sciences of the United States of America·Natalie HesselgraveScott M Thompson
Apr 17, 2021·ACS Pharmacology & Translational Science·David B Yaden, Roland R Griffiths
Apr 17, 2021·ACS Pharmacology & Translational Science·Calvin LyDavid E Olson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Texas Medicine
D Mulkey
Semaine médicale professionelle et médico-sociale
Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry
K K KRISTENSEN
© 2021 Meta ULC. All rights reserved